Pfizer Inc. (PFE): Price and Financial Metrics


Pfizer Inc. (PFE): $52.79

-1.26 (-2.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PFE POWR Grades


  • Growth is the dimension where PFE ranks best; there it ranks ahead of 97.14% of US stocks.
  • PFE's strongest trending metric is Growth; it's been moving up over the last 163 days.
  • PFE's current lowest rank is in the Momentum metric (where it is better than 12.47% of US stocks).

PFE Stock Summary

  • PFE has a higher market value than 99.5% of US stocks; more precisely, its current market capitalization is $303,375,439,622.
  • PFE's went public 36.08 years ago, making it older than 92.74% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of -36.85%, Pfizer Inc's debt growth rate surpasses merely 13.3% of about US stocks.
  • Stocks that are quantitatively similar to PFE, based on their financial statements, market capitalization, and price volatility, are ASML, XOM, DIS, TM, and KO.
  • Visit PFE's SEC page to see the company's official filings. To visit the company's web site, go to www.pfizer.com.

PFE Valuation Summary

  • PFE's price/sales ratio is 5; this is 55.95% lower than that of the median Healthcare stock.
  • PFE's price/sales ratio has moved down 2.9 over the prior 243 months.
  • Over the past 243 months, PFE's price/earnings ratio has gone down 17.6.

Below are key valuation metrics over time for PFE.

Stock Date P/S P/B P/E EV/EBIT
PFE 2021-08-31 5.0 3.7 19.5 20.3
PFE 2021-08-30 5.1 3.7 19.8 20.5
PFE 2021-08-27 5.1 3.7 19.8 20.5
PFE 2021-08-26 5.1 3.8 20.1 20.8
PFE 2021-08-25 5.2 3.8 20.1 20.8
PFE 2021-08-24 5.3 3.9 20.5 21.2

PFE Growth Metrics

    Its year over year net income to common stockholders growth rate is now at -29.76%.
  • Its 3 year revenue growth rate is now at 5.62%.
  • Its 3 year net income to common stockholders growth rate is now at 51.01%.
Over the past 49 months, PFE's revenue has gone up $11,129,000,000.

The table below shows PFE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 63,600 32,291 19,180
2021-06-30 51,637 23,552 13,228
2021-03-31 44,461 15,808 11,091
2020-12-31 41,908 14,403 9,616
2020-09-30 48,648 12,547 8,685
2020-06-30 49,197 14,967 14,171

PFE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PFE has a Quality Grade of B, ranking ahead of 88% of graded US stocks.
  • PFE's asset turnover comes in at 0.312 -- ranking 146th of 682 Pharmaceutical Products stocks.
  • XBIT, NERV, and BLUE are the stocks whose asset turnover ratios are most correlated with PFE.

The table below shows PFE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-04 0.312 0.704 0.149
2021-04-04 0.265 0.763 0.116
2020-12-31 0.247 0.793 0.099
2020-09-27 0.282 0.799 0.083
2020-06-28 0.288 0.799 0.181
2020-03-29 0.307 0.799 0.200

PFE Price Target

For more insight on analysts targets of PFE, see our PFE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $46.03 Average Broker Recommendation 1.8 (Hold)

PFE Stock Price Chart Interactive Chart >

Price chart for PFE

PFE Price/Volume Stats

Current price $52.79 52-week high $61.71
Prev. close $54.05 52-week low $33.36
Day low $52.46 Volume 41,058,902
Day high $54.87 Avg. volume 37,956,980
50-day MA $54.57 Dividend yield 2.96%
200-day MA $45.24 Market Cap 296.30B

Pfizer Inc. (PFE) Company Bio


Pfizer Inc. is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products. Pfizer was founded under its original name, Charles Pfizer & Company, in 1849 in Brooklyn, New York by Charles Pfizer and Charles Erhart. The company operates research and development facilities in United States and the United Kingdom and employs over 78,000 individuals worldwide. Some of the company’s more recognizable brands include Advil, Celebrex, Chantix, Chapstick, Dimetapp, Lipitor, Robitussin, and Viagra. Albert Bourla serves as Pfizer’s Chairman of the Board and Chief Executive Officer and the company is headquartered in New York, New York.


PFE Latest News Stream


Event/Time News Detail
Loading, please wait...

PFE Latest Social Stream


Loading social stream, please wait...

View Full PFE Social Stream

Latest PFE News From Around the Web

Below are the latest news stories about Pfizer Inc that investors may wish to consider to help them evaluate PFE as an investment opportunity.

Pfizer, OPKO receive somatrogon Complete Respoinse Letter for growth hormone deficiency

The FDA has issued Pfizer (NYSE:PFE) and OPKO Health (NASDAQ:OPK) a Complete Response Letter for their Biologics License Application ("BLA") for somatrogon. OPKO shares are down 9% in after-hours trading. The candidate is a once-weekly, long-acting recombinant human growth hormone for the treatment of pediatric growth hormone deficiency. Pfizer is examining the...

Seeking Alpha | January 21, 2022

U.S. FDA declines to approve Pfizer''s growth hormone deficiency treatment

Pfizer Inc said on Friday the U.S. health regulator has declined to approve the treatment for growth hormone deficiency in children that it developed with partner OPKO Health Inc .

Reuters | January 21, 2022

Booster Covid shots significantly improve protection against Omicron: Studies

They found vaccine effectiveness was best after three doses of the Pfizer or Moderna vaccines in preventing Covid-19-associated emergency department and urgent care visits

Livemint | January 21, 2022

WHO advisory panel recommends extending use of Pfizer vaccine to 5-11 year olds

The World Health Organization''s advisory panel on Friday recommended extending the use of a reduced dosage of Pfizer and German partner BioNTech''s COVID-19 vaccine to children aged 5 to 11 years old.

Reuters | January 21, 2022

Thinking about trading options or stock in Peloton Interactive, Apple, Walt Disney, Pfizer, or Nvidia?

NEW YORK , Jan. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTON, AAPL, DIS, PFE, and NVDA. Full story available on Benzinga.com

Benzinga | January 21, 2022

Read More 'PFE' Stories Here

PFE Price Returns

1-mo N/A
3-mo 22.25%
6-mo 23.67%
1-year 50.08%
3-year 53.81%
5-year 115.05%
YTD -10.60%
2021 66.69%
2020 3.23%
2019 -6.91%
2018 24.82%
2017 15.90%

PFE Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full PFE Dividend History

Continue Researching PFE

Want to see what other sources are saying about Pfizer Inc's financials and stock price? Try the links below:

Pfizer Inc (PFE) Stock Price | Nasdaq
Pfizer Inc (PFE) Stock Quote, History and News - Yahoo Finance
Pfizer Inc (PFE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0024 seconds.